IKONISYS Original-Research: Ikonisys SA (von Sphene Capital GmbH): Buy

Directive transparence : information réglementée

09/02/2022 09:21

Original-Research: Ikonisys SA - von Sphene Capital GmbH

Einstufung von Sphene Capital GmbH zu Ikonisys SA

Unternehmen: Ikonisys SA
ISIN: FR00140048X2

Anlass der Studie: Update Report
Empfehlung: Buy
seit: 09.02.2022
Kursziel: EUR 7,70 (unverändert)
Kursziel auf Sicht von: 24 Monate
Letzte Ratingänderung: -
Analyst: Peter Thilo Hasler, CEFA

Important client-win in Italy

After the first sale of the new-gen microscope, the Ikoniscope20, to one of the biggest genetic laboratories in Italy, we confirm our Buy rating for the shares of Ikonisys and our three-stage discounted cash flow entity model (primary valuation method) share price target of EUR 7.70.

Ikonisys announced the sale and installation of the Ikoniscope20 at Toma Advanced Biomedical Assays Spa ('TomaLab') in Busto Arsizio near Milan. TomaLab has been successfully validating the Ikoniscope20 for routine FISH testing in oncology, using several applications that span from lung cancer (oncoFISH ALK) to bladder cancer (oncoFISH bladder).

With revenues of more than EUR 20m and approximately 100 employees, TomaLab is one of the biggest accredited medical analysis laboratories in Italy, offering a full range of genetic diagnostic services in oncology, reproduction, ophthalmology, cardiology, and forensic genetics. The company operates specialised departments for clinical biochemistry and toxicology, microbiology and virology, pathological anatomy, cytogenetics and medical genetics.

According to Ikonisys, TomaLab will continue to collaborate on the development of novel applications for tests that will be of particular interest in the field of cancer diagnostics, especially regarding the Ikoniscope's ability to perform both FISH- and antibody-based tests. In addition, due to the particularly high level of qualification, TomaLab will act as a reference laboratory for Ikonisys. Potential clients of Ikonisys will be informed by TomaLab about the advantages and special characteristics of the Ikoniskope20. In our view this could significantly shorten the sales cycle for Ikonisys in the future.

Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/23345.pdf

Kontakt für Rückfragen
Peter Thilo Hasler, CEFA
+49 (89) 74443558/ +49 (152) 31764553

-------------------übermittelt durch die EQS Group AG.-------------------

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

23/06/2022 15:46
09/05/2022 15:51
04/05/2022 23:32
09/02/2022 09:21
25/01/2022 11:56